Clinical-stage drug development offers big rewards—and big risks. | This week on "The Top Line," we dive into several of the ...

As part of an agreement announced two weeks ago, eye-disease-focused Acelyrin was due to be absorbed into immune-mediated ...

The NIH has lost two distinguished leaders as mass layoffs directed by the Trump administration hit federal health agencies.

Illumina is raising the curtain on its upcoming entry into spatial transcriptomics, with tech designed to help researchers ...

On Jan. 2, Hookipa inked a non-binding agreement that would have created a merged company with Poolbeg via an all-stock ...

The wearable cardiac monitor maker VitalConnect has raised $100 million in new capital to aid in the development of its ...

BioMed X Institute is teaming up with the Barbados government in an effort to accelerate cardiometabolic treatments for ...

The R&D head is looking for "clever science," which Friberg said is readily apparent in BioMarin’s recent research pact with CAMP4 Therapeutics. The partners are using CAMP4’s regulatory RNA platform ...

“Partnering with Genesis Therapeutics presents a unique opportunity to leverage their AI technologies to accelerate the ...

UroGen Pharma has opened another front in its attack on bladder cancer, paying IconOVir Bio $4 million in stock for an ...

While the FDA’s diversity guidance for clinical trials has been temporarily restored, the page it is housed on now carries a ...

CRISPR-based Spotlight Therapeutics has shut down, former CEO Mary Haak-Frendscho, Ph.D., confirmed with Fierce Biotech. | ...